Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting ß2 adrenergic agonist (budesonide / formoterol) versus standard of care on the evolution of the disease in vulnerable patients with COVID-19: INHALAVID Trial